Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Relapsing polychondritis (RP) is a rare autoimmune disease affecting the multiple organ system. Here, we describe a case of RP initially presenting with high fever. The patient was referred to our hospital for further examination of fever of unknown origin (FUO). On admission, the patient reported dry cough in addition to fever. On physical examination, her red, swollen ears were noted, attributed on histology to inflammation with auricular perichondritis. She was diagnosed with RP and treated with oral prednisone (50 mg/day); her fever and auricular inflammation resolved. The patient no longer reported cough and body temperature returned to normal and the elevated levels of C-reactive protein (CRP) were normalized. In this case, identification of the origin of fever was a challenge because of unspecific symptoms; however, awareness of the systemic manifestations of RP may lead to the prompt diagnosis and therapeutic intervention.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769741PMC
http://dx.doi.org/10.1155/2016/9462489DOI Listing

Publication Analysis

Top Keywords

relapsing polychondritis
8
fever
6
case relapsing
4
polychondritis initiating
4
initiating unexplained
4
unexplained fever
4
fever relapsing
4
polychondritis rare
4
rare autoimmune
4
autoimmune disease
4

Similar Publications

A Case of Relapsing Polychondritis with Multisystemic Involvement.

Clin Cosmet Investig Dermatol

August 2025

Department of Imaging, The Fifth People's Hospital of Hainan Province, Haikou, Hainan, People's Republic of China.

Relapsing polychondritis is a rare immunologic disorder that can involve all cartilage and proteoglycan-rich tissues. Clinical symptoms of relapsing polychondritis are often associated with recurrent inflammatory manifestations and functional impairment of such tissues. The disease has an insidious onset, and the first symptoms and clinical manifestations vary, making it easy to misdiagnose and miss the diagnosis.

View Article and Find Full Text PDF

Background: Up to 22% of cancer patients treated with immune checkpoint inhibitors (ICIs) can experience immune-related adverse events (irAEs) that mimic rheumatic disease, such as relapsing polychondritis (RP), which is a rare autoimmune disease that mainly manifests as inflammation of airway cartilage.

Methods: We report a case of RP induced by humanized recombinant anti-PD-1 monoclonal antibody therapy (tislelizumab). 18F-Fluorodeoxyglucose positron emission tomography/ computed tomography (18F-FDG PET/CT) contributed to the diagnosis of RP, and methylprednisolone was used to effectively control its progression.

View Article and Find Full Text PDF

VEXAS syndrome (Vacuoles, E1-enzyme, X-linked, Autoinflammation, and Somatic) is a recently identified late-onset autoinflammatory disorder characterized by a unique interplay between hematological and inflammatory manifestations. It results from somatic mutations in the gene, located on the short arm of the X chromosome. Initially, females were considered mere carriers, with the syndrome primarily affecting males over 50.

View Article and Find Full Text PDF

Rationale: Relapsing polychondritis is a rare autoimmune disease that commonly leads to tracheobronchial stenosis, presenting significant treatment challenges.

Patient Concerns: This case report describes a 64-year-old male with relapsing polychondritis who developed severe tracheobronchial stenosis.

Diagnoses: Computed tomography scanning revealed stenosis of the trachea and bronchi, while bronchoscopy confirmed occlusion or stenosis.

View Article and Find Full Text PDF

Background: Tracheobronchomegaly, also known as Mounier-Kuhn syndrome (MKS), is a rare congenital condition characterized by significant dilation of the trachea and main bronchi along with an abnormal wall structure. Diagnosis can be confirmed through computed tomography, pulmonary function tests, and diagnostic bronchoscopy. Currently, there is no curative treatment for MKS; thus, symptomatic and supportive care remain the primary therapeutic approaches.

View Article and Find Full Text PDF